Perioperative hepatic arterial infusion pump chemotherapy is associated with longer survival after resection of colorectal liver metastases: A propensity score analysis Journal Article


Authors: Koerkamp, B. G.; Sadot, E.; Kemeny, N. E.; Gönen, M.; Leal, J. N.; Allen, P. J.; Cercek, A.; DeMatteo, R. P.; Kingham, T. P.; Jarnagin, W. R.; D’Angelica, M. I.
Article Title: Perioperative hepatic arterial infusion pump chemotherapy is associated with longer survival after resection of colorectal liver metastases: A propensity score analysis
Abstract: Purpose: To investigate whether perioperative hepatic arterial infusion pump chemotherapy (HAI) was associated with overall survival (OS) in patients who had a complete resection of colorectal liver metastases (CLM). Methods: Patients who underwent a complete resection of CLM between 1992 and 2012 were included from a single-center prospectively maintained database. All patients who received HAI also received perioperative systemic chemotherapy. Propensity score analysis was used to match patients for seven known prognostic factors. Results: A total of 2,368 consecutive patients underwent a complete resection of CLM, with a median followup of 55 months. The median OS for patients with HAI (n = 785) was 67 months versus 44 months without HAI (n = 1,583; P, .001), despite more advanced disease in the HAI group. OS at 10 years was 38.0% versus 23.8% without HAI. For patients who received modern systemic chemotherapy (n = 1,442), the median OS was 67 months with HAI and 47 months without HAI (P, .001). The hazard ratio adjusted by propensity score demonstrated longer OS with HAI: 0.67 (95% CI, 0.59 to 0.76; P, .001). A pronounced difference in median OS was found for patients with node-negative colorectal cancer (129 months with HAI v 51 months without; P, .001) and a low clinical risk score of 0 to 2 points (89 months with HAI v 53 months without; P, .001). Conclusion: Patients who received HAI had a median OS of approximately 2 years longer than patients without HAI. The strong association was independent of the use of modern systemic chemotherapy and remained in propensity score analysis. Patients with node-negative primary tumors or a low clinical risk score seemed to benefit most from HAI. © 2017 by American Society of Clinical Oncology.
Journal Title: Journal of Clinical Oncology
Volume: 35
Issue: 17
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2017-06-01
Start Page: 1938
End Page: 1944
Language: English
DOI: 10.1200/jco.2016.71.8346
PROVIDER: scopus
PMCID: PMC5466010
PUBMED: 28426374
DOI/URL:
Notes: Article -- Export Date: 2 August 2017 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Ronald P Dematteo
    588 Dematteo
  2. Mithat Gonen
    687 Gonen
  3. Peter Allen
    427 Allen
  4. William R Jarnagin
    569 Jarnagin
  5. T Peter Kingham
    281 Kingham
  6. Nancy Kemeny
    334 Kemeny
  7. Julie Leal
    12 Leal
  8. Eran Sadot
    35 Sadot